Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.